David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more. 

Eyenuk Inc. founder and CEO Kaushal Solanki, PhD, went from working for the Defense Department to founding a company with a focus on artificial intelligence for ophthalmology. Find out what led him to make that jump.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

Dr. Jai Parekh, a clinical associate professor of Ophthalmology/The New York Eye & Infirmary of the Mount Sinai School of Medicine and David Hutton, Managing Editor of Ophthalmology Times discuss the importance of ocular health prior to cataract and refractive surgery, specifically with osmolarity testing.

On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the discussion with Ophthalmology Times® executive editor, David Hutton.

Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Colin hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.

In this episode of EyePod, Ora Clinical’s Keith Lane discusses uveitis and flare ups, as well as challenges in clinical trials.

Keith Lane of Orange Clinical joins us to discuss the current state of gene therapy and its standardized endpoints, and the challenges gene therapy has faced, particularly in relation to ophthalmology.

Retinopathy of prematurity expert C. Armitage Harper, III, MD, of the Austin Retina Associates in Austin, Texas, discusses his experience in treating ROP cases across the globe, and his mission prevent pre-term blindness in infants. 

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.